Barclays Maintains an 'Equalweight' on Onyx Pharmaceuticals (ONXX); $4 Upside if MISSION Works

Barclays maintains an 'Equalweight' on Onyx Pharmaceuticals (NASDAQ: ONXX) price target of $40.00.

Analyst, Ying Huang, said, "MISSION survival data in 3rd/4th line non-small cell lung cancer (NSCLC) is expected soon in 1H12. With Nexavar's history of noteworthy Phase III front-line NSCLC failures in ESCAPE and NExUS, it is easy to dismiss any chance of MISSION success. However, Nexavar has also shown encouraging results more recently in two smaller Phase II trials (ECOG 2501 and BATTLE)."

Huang feels that positive results on MISSION could add $4 upside to ONXX shares, but currently doesn't hold high conviction on the outcome.

For an analyst ratings summary and ratings history on Onyx Pharmaceuticals click here. For more ratings news on Onyx Pharmaceuticals click here.

Shares of Onyx Pharmaceuticals closed at $37.26 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• HSBC Downgrades Feng Tay Enterprises (9910:TT) to Hold
• Liberty Oilfield Services (LBRT) PT Raised to $21 at TD Cowen
• Rubrik IPO: 5 key things to know